Five early planning strategies for biotechs

In drug development, early and simultaneous management of commercial, clinical, regulatory, and market access strategy is the surest path to approval, investment, reimbursement, and market share. Get the Parexel Biotech perspective on early strategies for bringing new treatments to the patients who need them.

Download eBook

Leadership Lessons on Diversity, Equity, & Inclusion, and the Future of Work

Featuring Jamie Macdonald, CEO, Parexel & Amir Kalali, Chairman & Chief Curator, CNS Summit

Created as part of CNS Summit 2021, a year-round experience designed for R&D Leaders in Life Sciences, the full discussion is now available here. 

Watch now

Navigating Long COVID Syndrome

During this time, we continue to be committed to our customers’ business while putting the safety of patients, partners and our employees at the heart of everything we do.

Long COVID Syndrome

COVID-19 Response

COVID-19 Data Clearinghouse

Four strategies for oncology drug development in a post-COVID world

COVID-19 has changed every aspect of drug development. From novel endpoints to the advanced adoption of real-world evidence to decentralized trial designs, Parexel's experts and one insightful patient explore what new imperatives oncology drug developers can adopt to speed life-changing therapies to patients in need in this new eBook.

Download now

Risk-based Quality Management (RBQM) Services

The new world order of clinical research demands a fresh look at end-to-end clinical practices. Parexel’s approach to risk-based quality management (RBQM) is a holistic risk strategy rooted in Quality by Design principles, that relies on critical data to inform decision-making throughout clinical programs and trials.

Learn more